Avita Medical, Inc.
As of Oct 22, 2026, Avita Medical is in Stage 2, the uptrend phase, now in week 13 (since Jul 24, 2026). It closed at $15.42, at its 52-week high and above its 200-day average, which is rising.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is RCEL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RCEL among Medical Devices2nd of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
Avita Medical: quick answers
What stage is Avita Medical in?
As of Oct 22, 2026, Avita Medical (RCEL) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 24, 2026 and is in week 13. What the four stages mean
Is Avita Medical in an uptrend?
Yes. Avita Medical is in a Stage 2 uptrend. It trades 149.7% above its 200-day average, which is rising.
How far is Avita Medical from its 52-week high?
Avita Medical closed at $15.42 on Oct 22, 2026, at its 52-week high. Its 52-week low is $3.27.
How has Avita Medical performed over the past year?
As of Oct 22, 2026, Avita Medical is up 274.3% over the past year and up 344.4% so far in 2026.
Which sector and industry is Avita Medical in?
Avita Medical is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.